Michael Myers - 04 Feb 2026 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael Myers
Issuer symbol
QNRX
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
4
Filing time
06 Feb 2026, 17:18:44 UTC
Previous filing
13 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Myers Michael Chief Executive Officer, Director C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN /s/ Michael Myers 06 Feb 2026 0001959547

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNRX Share Option (Right to Buy) Award $0 +318,750 $0.000000 318,750 04 Feb 2026 ADS 318,750 $7.37 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.